Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp

Matsuhashi, N, MD1,*; Nakajima, A, MD1; Shinohara, K, MD1; Oka, T, MD1; Yazaki, Y, PhD1

American Journal of Gastroenterology: November 1998 - Volume 93 - Issue 11 - p 2261–2266
doi: 10.1111/j.1572-0241.1998.00630.x
Case Reports: PDF Only

Like adenomatous polyps in familial adenomatous polyposis, some sporadic colorectal polyps have been reported to regress in response to sulindac administration. However, a rapidly growing invasive rectal cancer developed in one of 15 patients with sulindac-treated sporadic adenomatous colorectal polyps 16 months after sulindac treatment. In this patient, both the adenomatous polyp that responded partially to sulindac and the rectal cancer developing after sulindac therapy showed immunostaining for cyclooxygenase-2. Although short term sulindac therapy seems to be able to cause some adenomatous colorectal polyps to regress, 4 months of sulindac therapy may not reliably prevent colorectal cancer development in these patients.

1Third Department of Internal Medicine, Second Department of Surgery, and Department of Pathology, Faculty of Medicine, University of Tokyo, Tokyo, Japan

*The Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan

© The American College of Gastroenterology 1998. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website